Latest Blogs

Oct 15, 2021
It is encouraging and enlightening to know that breast cancer awareness campaigns are being conducted all over the world, even in countries troubled with major political and military conflicts.
Oct 13, 2021
The Hem-Onc Fellows Network is committed to promoting diversity, equity, and inclusion in hematology-oncology, said Mrs. Andrea Anampa-Guzmán, Dr. Muhammad Salman Faisal, and Dr. Aakash Desai. 
Oct 07, 2021
In Volume 3 of his series, Dr. Dawood Findakly provides guidance on the virtual fellowship interview process. 
Oct 06, 2021
When a patient comes to me for help with a problem, I am often the one who learns a life lesson in grace and humanity.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a professor emeritus at the University of Colorado Cancer Center. He previously served as chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Disclosure.

Jun 02, 2014
Adding 6 cycles of docetaxel at the outset of hormonal therapy for prostate cancer has been shown to improve survival, especially in men with a high burden of disease. The much-...
Apr 18, 2014
So how did the robot take over? As I recall, it started with "hospital A" buying the fancy robot for their urologists to use, after said urologists insisted that this was the way of the future. The Intuitive Surgical Company did an...
Mar 10, 2014
A new article appeared this week with further fuel for those on the side of intervention (and by implication, pro-screening). Let's remember before we get started that the two...
Feb 07, 2014
Long, long ago, I had just finished my fellowship in medical oncology and moved from Boston to Denver. In the lab, I was working on an obscure enzyme that seemed to differentiate leukemia from normal cells,cystathionase. In...
Jan 15, 2014
These two questions are among the most commonly asked in my clinic, particularly from patients who are recently diagnosed with prostate cancer.
Jun 04, 2012
Since I have no formal training in either of these disciplines, it is either possible (or likely) that I will say things that offend both camps. In three of the presentations at ASCO this week in which I have great interest professionally (prostate cancer), questions have arisen that bring these...

Pages